Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 44Pancreatic Neoplasms 37Carcinoma, Non-Small-Cell Lung 37Triple Negative Breast Neoplasms 28Ovarian Neoplasms 20Fallopian Tube Neoplasms 19Lung Neoplasms 15Squamous Cell Carcinoma of Head and Neck 13Neoplasm Metastasis 11Uterine Cervical Neoplasms 8Melanoma 7Inflammatory Breast Neoplasms 7Esophageal Squamous Cell Carcinoma 6Breast Neoplasms, Male 6Stomach Neoplasms 5Cholangiocarcinoma 5Brenner Tumor 5Pancreatic Adenocarcinoma 4Neoplasms 4Esophageal Neoplasms 4Carcinoma, Transitional Cell 4Adenocarcinoma, Bronchiolo-Alveolar 4Adenocarcinoma of Lung 4Adenocarcinoma Of Esophagus 4Urinary Bladder Neoplasms 3Pleural Effusion, Malignant 3Oropharyngeal Neoplasms 3Nasopharyngeal Carcinoma 3Mouth Neoplasms 3Endometrial Neoplasms 3

Interventions

Taxes 1Radiotherapy 1Radiation 1Paclitaxel 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Hemoptysis × Taxes × Clear all
NCT00387374 2013-01-17

Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer at High Risk for Hemoptysis Caused by Bevacizumab

National Cancer Institute (NCI)

Phase 2 Completed
72 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Hemoptysis, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡